The Problem: Diabetic Neuropathy
10% of Americans have diabetes and the number is increasing by 5% each year1
– 88 million American adults — approximately 1 in 3 have prediabetes
50% – 66% of diabetic adults, during their lifetime, suffer Peripheral Neuropathy — associated with: substantial morbidity including pain, foot ulcers, and lower limb amputation2
95% of all diabetics have evidence of nerve damage3,4
20% -30% of diabetic adults suffer Autonomic Neuropathy (DAN) — including: instability of cardiac rhythm and blood pressure, loss of normal control of the gastro-intestine tract, impacted control of the bladder, and impotence5
Both somatic (sensory) nerves and autonomic nerves can be affected:
- Kelsey, J-S, Smith, AG, “Updates in diabetic peripheral neuropathy,” F1000Research 2016, 5(F1000 Faculty Rev):738 Last updated: 25 APR 2016; “National Diabetes Statistics Report, 2020,” https://www.cdc.gov/diabetes/library/features/diabetesstat-report.html.
- Hicks, CW, Selvin, E, “Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes,” Curr Diab Rep.; 19(10): 86. doi:10.1007/s11892-019-1212-8; Pirart J., “Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973,” Diabetes Care 1978; 1(3): 168-183; Wu, J, et al., “PGE1 improves diabetic peripheral neuropathy in patients with type 2 Diabetes,” Prostaglandins & Other Lipid Mediators 126 (2016) 24-28.
- Dyck PJ, Thomas PK, Asbury AK et al (eds). Diabetic Neuropathy. Saunders, Philadelphia, 1987.
- Andreani D, et al., (eds). Diabetic Complications: Early Diagnosis and Treatment. John Wiley, Chichester, 1987.
- Vinik, AI, et al., “Diabetic Autonomic Neuropathy,” Diabetes Care 26:1553–1579, 2003.
Novel lipids-based pharmacognosy solutions
Treatment of diseases and disorders of impaired Δ-6 desaturase / inflammation